(2022) (156), developed the first humanized third-generation CAR-targeting IL-13Rα2 that showed great anti-tumor efficacy and reduced expression of immunosuppressive cytokines such as IL-6 (88, 157) Like second and third generation IL-13Rα2-targeted CAR-T cells, HER2-specific, 41BB-costimulatory CAR with a truncated CD19 have been engineered and are being assessed in recurrent or non-responsive glioblastoma (NCT03389230, Table 2). This evidence concerns the gene IL13RA2 and neoplasm.